Characteristics | MSK-GI cohort (n = 227) | Janjigian cohort (n = 40) | PUCH cohort (n = 80) |
---|---|---|---|
Age (years) | |||
≥ 65 | 74 (32.6%) | 18 (45.0%) | 22 (27.5%) |
< 65 | 153 (67.4%) | 22 (55.0%) | 58 (72.5%) |
Gender | |||
Male | 152 (67.0%) | 33 (82.5%) | 56 (70.0%) |
Female | 75 (33.0%) | 7 (17.5%) | 24 (30.0%) |
Tumor type | |||
Esophagogastric cancer | 118 (52.0%) | 40 (100.0%) | 60 (75.0%) |
Colorectal cancer | 109 (48.0%) | 0 (0%) | 20 (25.0%) |
Metastasis | |||
Yes | 98 (43.2%) | 27 (67.5%) | 100 (100%) |
No | 129 (56.8%) | 13 (32.5%) | 0 (0%) |
PD-L1 | |||
Positive | NA | 13 (32.5%) | 29 (36.3%) |
Negative | 6 (15.0%) | 27 (33.8%) | |
NA | 21 (52.5%) | 24 (30.0%) | |
MSI status | |||
MSI-H/dMMR | NA | 5 (12.5%)a | 22 (27.5%) |
MSI-L/MSS/pMMR | 35 (87.5%) | 44 (55.0%) | |
NA | 0 (0%) | 14 (17.5%) | |
Drug type | |||
Anti-PD-1/PD-L1 therapy | 185 (81.5%) | 26 (65.0%) | 69b (86.3%) |
Anti-CTLA-4 therapy | 3 (1.3%) | 0 (0%) | 0 (0%) |
Anti-PD-1/PD-L1+anti-CTLA-4 therapy | 39 (17.2%) | 14 (35.0%) | 11 (13.8%) |
Percentages might not total 100% because of rounding. NA, not available. aMSI sensor method was used to evaluated MSI status in the Janjigian cohort. Samples with a score ≥ 10 were classified as MSI-H. bThree patients received PD-1 inhibitor plus chemotherapy, and 1 patient received PD-1 inhibitor plus apatinib. MSI = microsatellite instability